Phase I Study of the BBP-398 in Chinse Patients With Advance Solid Tumors
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation and expansion, two-part Phase I study for SHP-2
inhibitor BBP-398 to evaluate the safety, tolerability, pharmacokinetics, determine MTD
and/or RP2D, and preliminary anti- cancer activity in Chinese subjects with advanced solid
tumors and in Chinese subjects with advanced or metastatic EGFR-mutant NSCLC.